Small J G, Milstein V, Marhenke J D, Hall D D, Kellams J J
J Clin Psychiatry. 1987 Jul;48(7):263-7.
Thirty-eight chronically ill psychotic patients were treated with clozapine for indications of tardive dyskinesia, severe extrapyramidal side effects caused by other neuroleptics, or treatment-resistant psychosis. Fifty-five percent of all patients and 40% of schizophrenics improved with clozapine. Abnormal involuntary movements were suppressed during treatment and, with 1 exception, returned to baseline levels after clozapine was discontinued. Our results support the conclusion that clozapine's efficacy in refractory cases and its lack of neurological side effects make it a unique neuroleptic with advantages over conventional antipsychotic agents. The drug appears to be safe when treatment is accompanied by frequent clinical and hematologic monitoring.
38例慢性病理性精神病患者接受了氯氮平治疗，用于治疗迟发性运动障碍、其他抗精神病药物引起的严重锥体外系副作用或难治性精神病。所有患者中有55%、精神分裂症患者中有40%在使用氯氮平后病情改善。治疗期间异常不自主运动受到抑制，除1例患者外，停用氯氮平后均恢复至基线水平。我们的结果支持以下结论：氯氮平在难治性病例中的疗效及其缺乏神经学副作用，使其成为一种独特的抗精神病药物，优于传统抗精神病药物。当治疗伴有频繁的临床和血液学监测时，该药物似乎是安全的。
